Basilea Working With European Antibiotics Project To Develop BAL30072 For Bronchiectasis, CF
News
Basilea, a Swiss-based pharmaceutical company, recently announced that they are developing a new formulation of BAL30072, a monosulfactam antibiotic with bactericidal activity against multidrug-resistant gram-negative bacteria, as part of a Europe-wide program that ... Read more